Verition Fund Management
BIS icon

Verition Fund Management’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Verition Fund Management’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-420
Closed -$202K – 376
2014
Q3 		$202K Buy
+420
New +$224K 0.03% 562

Other funds holding BIS

HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
KC
Kingfisher Capital Charlotte, North Carolina $437M AUM 41.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Verition Fund Management's BIS Position: Q4 2014 in Review

Verition Fund Management sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q4 2014, closing a stake of 420 shares — an estimated $202K sold.

Verition Fund Management first reported a position in BIS in Q3 2014 and held it in 1 quarter. The position peaked at $202K in Q3 2014. 9 funds tracked by Wall St. Rank hold BIS as of Q4 2014.

  • Verition Fund Management reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q4 2014 after selling out during the quarter.
  • Verition Fund Management sold 420 ProShares UltraShort NASDAQ Biotechnology shares in Q4 2014, an estimated $202K.
  • Verition Fund Management first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q3 2014 and held it in 1 quarter.
  • Verition Fund Management's ProShares UltraShort NASDAQ Biotechnology position peaked at $202K in Q3 2014.
  • 9 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q4 2014.

Based on Verition Fund Management's 13F filing for Q4 2014, filed 13 Feb 2015.